Curtis Mello, MD
Pulmonary Disease · North Dartmouth, MANPI 1124080312
Payments from drug & device makers
Across 948 payments — averaging $1964.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$412K
- Sanofi US Services Inc.$295K
- GSK$284K
- Daiichi Sankyo Inc.$195K
- Boehringer Ingelheim$177K
- Novo Nordisk AS$107K
- plus $393K from 28 others
Across 12 payments — averaging $398.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ensodata, Inc.$3K
- Eli Lilly$2K
- GSK$191
- Teva Pharmaceuticals USA, Inc.$157
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 158 | $411,504 |
| Sanofi US Services Inc. | 21 | $294,818 |
| GSK | 106 | $284,138 |
| Daiichi Sankyo Inc. | 127 | $194,524 |
| Boehringer Ingelheim | 133 | $177,402 |
| Novo Nordisk AS | 131 | $106,939 |
| Chiesi USA, Inc. | 18 | $98,630 |
| Teva Pharmaceuticals USA, Inc. | 43 | $91,916 |
| Mylan Specialty L.p. | 34 | $60,075 |
| Boehringer Ingelheim International GmbH | 82 | $40,574 |
| Eli Lilly | 19 | $38,164 |
| Regeneron | 9 | $32,833 |
| United Therapeutics Corporation | 2 | $11,595 |
| Genentech, Inc. | 4 | $9,505 |
| Ensodata, Inc. | 1 | $5,000 |
| Viatris Specialty LLC | 5 | $3,037 |
| Jazz Pharmaceuticals Inc. | 12 | $353 |
| Amgen | 11 | $245 |
| Sanofi | 5 | $142 |
| Harmony Biosciences LLC | 6 | $136 |
| Inspire Medical Systems, Inc. | 2 | $125 |
| Insmed, Inc. | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Pfizer | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Verona Pharma, Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Merck | 1 | $26 |
| Novartis | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| 3b Medical, Inc. | 1 | $21 |
| Electromed, Inc. | 2 | $20 |
| Phadia US Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
How this compares
$1,862,153 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in North Dartmouth
- Christos KapogiannisNorth Dartmouth$65K
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Gary HunninghakeBoston$1.5M
- Elliot IsraelBrookline$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.